2011
DOI: 10.1111/j.1600-0560.2011.01722.x
|View full text |Cite
|
Sign up to set email alerts
|

Lymph nodal Merkel cell carcinoma: primary tumor or metastasis from unknown primary site?

Abstract: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer with neuroendocrine differentiation (1-4). Most MCC affect the skin of the head and neck, often the periorbital region and the extremities; less than 10% affect the trunk or mucus membranes (1-5); regional lymph nodal metastases occur in 50 - 66% of the cases.\ud In 1992, Eusebi et al (5) described eight cases of nodal MCC in the absence of primary skin tumours or any other localization. Afterwards other authors (3,4) reported cases of “primary” nod… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
13
0

Year Published

2012
2012
2021
2021

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 14 publications
(13 citation statements)
references
References 7 publications
0
13
0
Order By: Relevance
“…A significant proportion of MCCUP patients (12.2%, 11/90) had a history of a previously or concurrent treated malignancy (eight basal cell carcinomas, one prostate cancer, three patients with chronic lymphocytic leukaemia), two patients were transplant recipients and another three patients were carriers of HIV. In the immunosupressed population an earlier median onset of the disease at 52 years (37-61) was observed [3,[11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30]. Almost all evaluable patients presented with clinically palpable non-tender lymph nodes-IIIB disease.…”
Section: Patients Characteristics and Clinical Presentationmentioning
confidence: 99%
See 1 more Smart Citation
“…A significant proportion of MCCUP patients (12.2%, 11/90) had a history of a previously or concurrent treated malignancy (eight basal cell carcinomas, one prostate cancer, three patients with chronic lymphocytic leukaemia), two patients were transplant recipients and another three patients were carriers of HIV. In the immunosupressed population an earlier median onset of the disease at 52 years (37-61) was observed [3,[11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30]. Almost all evaluable patients presented with clinically palpable non-tender lymph nodes-IIIB disease.…”
Section: Patients Characteristics and Clinical Presentationmentioning
confidence: 99%
“…Inguinal and axillary lymph node areas were initially involved in 40% (36/90) and 17.7% (16/90) of cases, respectively. Lesions ranged in colour from red, pink to blue of flesh-coloured, sometimes with a shiny surface which may mislead to a basal cell carcinoma diagnosis [11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29]. Characteristics of all patients are summarised in Table 1 and are displayed in details in Table 2.…”
Section: Patients Characteristics and Clinical Presentationmentioning
confidence: 99%
“…2 Rare cases of highgrade neuroendocrine tumor have been encountered in the lymph nodes with unknown extranodal primary, and these tumors were often described as 'Merkel cell carcinoma of lymph node with unknown primary' as they exhibit similar morphologic and immunophenotypic features to those in the skin Merkel cell carcinoma. [5][6][7][8][9][10][11][12][13][14] However, it is not clear whether the nodal Merkel cell carcinoma is a primary tumor of lymph node or represents a metastasis from an occult or regressed extranodal lesion. To establish an accurate diagnosis of nodal Merkel cell carcinoma can be challenging, and it has to be separated from other nodal metastatic neoplasms, such as small cell carcinoma and lymphoblastic lymphoma.…”
mentioning
confidence: 99%
“…Furthermore, in a significant part of cases from other institutions we were not able to get further information about the progress of disease. About MCC from unknown primary site (31% in our series), survival appears very low (average 24 months) but conditioned by a very significant late diagnosis up to 18 months, and few treatment options [85]. Finally, we believe that the comprehensive evaluation of the patient integrated with imaging and laboratory parameters can allow to find the right direction for a balanced choice of therapy and not always immediately easy.…”
Section: Discussionmentioning
confidence: 86%